Survey sheds light on glaucoma prevalence in West Africa

Region may have world’s highest rate, investigators say.

New Horizons Forum: Diagnostic advances in glaucoma

Investigators from various companies described their diagnostic offerings at the Glaucoma Research Foundation’s 2021 New Horizons Forum.

Teleglaucoma: Practice survival in the COVID-19 era

Telemedicine provides readiness in time of crisis.

The latest updates in cyclophotocoagulation

February 13, 2021

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

Intersection of glaucoma and retina at the pars plana

February 11, 2021

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

Managing secondary glaucoma due to intravitreal steroids

February 09, 2021

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Aerie COO: Expanding innovation of glaucoma therapeutics

February 06, 2021

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Glaukos COO shares product updates, 2021 pipeline

January 31, 2021

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.